Equities Analysts Issue Forecasts for RIGL Q1 Earnings

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Rigel Pharmaceuticals in a research note issued on Wednesday, March 4th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will earn $0.95 per share for the quarter. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is $0.22 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals’ Q2 2026 earnings at $1.20 EPS, FY2027 earnings at $3.85 EPS and FY2028 earnings at $4.42 EPS.

RIGL has been the subject of several other reports. Zacks Research upgraded Rigel Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 18th. Weiss Ratings reissued a “hold (c+)” rating on shares of Rigel Pharmaceuticals in a research note on Thursday, January 22nd. Citigroup restated a “buy” rating on shares of Rigel Pharmaceuticals in a report on Wednesday, January 14th. Finally, Wall Street Zen upgraded shares of Rigel Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Sunday, December 21st. Three equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.67.

Rigel Pharmaceuticals Stock Down 0.4%

Shares of NASDAQ RIGL opened at $29.52 on Thursday. The firm has a market cap of $545.23 million, a price-to-earnings ratio of 1.56 and a beta of 1.10. The company has a quick ratio of 2.14, a current ratio of 2.42 and a debt-to-equity ratio of 0.06. Rigel Pharmaceuticals has a 52-week low of $15.50 and a 52-week high of $52.24. The business’s 50 day moving average is $37.16 and its two-hundred day moving average is $37.32.

Institutional Investors Weigh In On Rigel Pharmaceuticals

Large investors have recently modified their holdings of the company. Invesco Ltd. lifted its position in shares of Rigel Pharmaceuticals by 24.1% during the 4th quarter. Invesco Ltd. now owns 34,921 shares of the biotechnology company’s stock worth $1,496,000 after purchasing an additional 6,790 shares during the last quarter. VARCOV Co. purchased a new position in Rigel Pharmaceuticals in the fourth quarter valued at $238,000. Verdad Advisers LP acquired a new stake in Rigel Pharmaceuticals in the fourth quarter valued at $372,000. Virtus Investment Advisers LLC purchased a new stake in Rigel Pharmaceuticals during the 4th quarter worth about $279,000. Finally, Quadrature Capital Ltd acquired a new position in shares of Rigel Pharmaceuticals during the 4th quarter worth about $506,000. 66.23% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Walter H. Moos sold 4,000 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $36.36, for a total value of $145,440.00. Following the sale, the director owned 12,722 shares of the company’s stock, valued at $462,571.92. This trade represents a 23.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 9.48% of the stock is currently owned by company insiders.

Key Rigel Pharmaceuticals News

Here are the key news stories impacting Rigel Pharmaceuticals this week:

• Positive Sentiment: Q4 earnings/call showed record net income and management highlighted pipeline progress and new targets, supporting longer‑term growth prospects. Rigel Pharmaceuticals Inc (RIGL) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: FY2026 revenue guidance was reiterated/updated to about $275M–$290M (vs. consensus ~$281.8M) — range overlaps consensus, so guidance is broadly in line but leaves room for volatility depending on contract revenue execution.
• Negative Sentiment: HC Wainwright trimmed its FY2027 and FY2028 EPS forecasts (FY27: from $3.92 to $3.85; FY28: from $4.73 to $4.42) and provided quarterly EPS projections, signaling tempered near‑term earnings expectations.
• Negative Sentiment: Analysts and coverage note risk to near‑term revenue: Seeking Alpha highlights falling contract revenue that could drive a revenue/earnings contraction, which likely pressured sentiment. Rigel Pharma stock slides as falling contract revenue to drive contraction
• Negative Sentiment: New disclosure flags FDA fast‑track ambitions carry significant regulatory uncertainty — adds execution risk for pipeline assets and could temper upside until clear regulatory paths are defined. Rigel Pharmaceuticals’ Fast Track Ambitions Face Significant FDA Uncertainty
• Negative Sentiment: Consensus analyst stance is “Hold,” reflecting mixed views on near‑term commercialization and revenue durability. Rigel Pharmaceuticals Receives Consensus Recommendation of “Hold”

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Rigel focuses on the discovery, development and commercialization of novel small molecule therapeutics targeting immune, hematologic and oncologic diseases. Leveraging a proprietary chemistry platform and expertise in signal transduction pathways, the company aims to address significant unmet medical needs in both rare and common disorders.

Rigel’s lead product, fostamatinib (commercially known as Tavalisse®), is an oral spleen tyrosine kinase (SYK) inhibitor approved in the United States for the treatment of adult patients with chronic immune thrombocytopenia (ITP).